[go: up one dir, main page]

WO1997036602A1 - Procede pour reconstituer une proteine fonctionnelle dans un tissu par transplantation de cellules - Google Patents

Procede pour reconstituer une proteine fonctionnelle dans un tissu par transplantation de cellules Download PDF

Info

Publication number
WO1997036602A1
WO1997036602A1 PCT/CA1996/000191 CA9600191W WO9736602A1 WO 1997036602 A1 WO1997036602 A1 WO 1997036602A1 CA 9600191 W CA9600191 W CA 9600191W WO 9736602 A1 WO9736602 A1 WO 9736602A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
transplantation
muscle
lama2
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA1996/000191
Other languages
English (en)
Inventor
Jacques P. Tremblay
Raynald Roy
Jean-Thomas Vilquin
Benoit Guerette
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Laval
Original Assignee
Universite Laval
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Laval filed Critical Universite Laval
Priority to AU51401/96A priority Critical patent/AU5140196A/en
Priority to PCT/CA1996/000191 priority patent/WO1997036602A1/fr
Priority to EP96907971A priority patent/EP0896542A1/fr
Priority to CA002260808A priority patent/CA2260808A1/fr
Publication of WO1997036602A1 publication Critical patent/WO1997036602A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • This invention relates to a method of restoring a
  • donor cells or genetically modified donor cells. More
  • the present method reduces the mortality
  • Myoblast transplantation may indeed be any one of several diseases. Myoblast transplantation may indeed be any one of several diseases. Myoblast transplantation may indeed be any one of several diseases. Myoblast transplantation may indeed be any one of several diseases. Myoblast transplantation may indeed be any one of several diseases. Myoblast transplantation may indeed be any one of several diseases. Myoblast transplantation may indeed be any one of several diseases. Myoblast transplantation may indeed be any one of several diseases. Myoblast transplantation may indeed be transplantation of several diseases.
  • transplantation may be used to treat Huntington disease
  • islet may be use for diabetic (Hering et al. 1993), hepatocytes for liver diseases (Raper and
  • transplantation are the following:
  • infiltrating cells may be observed at the site of
  • histocompatible host and donor are selected (matched for
  • antigens might be responsible for an observed immune
  • fibroblast growth factor is shown to increase by four ⁇
  • Inflammation may be one of the major factors involved in
  • Inflammation may be also a cell or humoral response. Inflammation may be also a cell or humoral response. Inflammation may be also a cell or humoral response. Inflammation may be also a cell or humoral response. Inflammation may be also a cell or humoral response. Inflammation may be also a cell or humoral response. Inflammation may be also a cell or humoral response. Inflammation may be also a cell or humoral response. Inflammation may be also
  • dystrophic mouse which was used was (C57BL/6J-dy 2 /dy 2J )
  • fibroblasts interfere with the practice of the claimed invention and cause detrimental
  • merosin a protein called merosin (Arahata et al . 1993; Sunada et
  • mice have an
  • Dr. Law's group is erroneous and thus the scientific
  • transplant survival one of the most serious problems: transplant survival.
  • tissue which comprises the steps of transplanting donor cells in a patient in need for such a transplantation
  • transplantation being made in the presence of an
  • blocking is effected by using an anti-ICAM-1 antibody
  • MHC class I and class II antigens MHC class I and class II antigens
  • immunosuppressive agents are rapamycin or FK506,
  • the immunosuppressors are used.
  • the donor cells might be selected from the group
  • these cells may be transplanted from a donor biopsy, these cells may be
  • the used promoter might be an inducible promoter.
  • cell proliferation is SV40-T antigen.
  • the promoter is SV40-T antigen.
  • this promoter is a MHC Class II gene
  • a MHC Class II promoter is inducible by ⁇ -
  • thermosensitive mutants thereof may be used.
  • myogenic cells may be required while for
  • the present invention provides for the first
  • transplantation of myoblasts eg. restoration of
  • dystrophin or the transplantation of non myogenic cells (eg. restoration of merosin) will achieve such results
  • the invention is based on successful
  • myoblasts by forming new muscle fibers or forming hybrid
  • muscle cells i.e. by fusing with host myoblasts or muscle fibers
  • the missing gene product e.g.
  • the missing gene product eg.
  • merosin may be secreted in the extracellular matrix.
  • the myogenic or non myogenic cells to be used.
  • transplanted can be histocompatible or histoincompatible
  • pharmacological agents such as cyclosporin-A, rapamycin
  • the immunosuppression may also be
  • lymphocytes or antigen presenting cell determinants are lymphocytes or antigen presenting cell determinants.
  • CD4 , anti-CD8 and anti-LFA-1 Mabs were both capable of
  • immunosuppressive agents may maintain long-term graft
  • the immunosuppressive treatment may therefore be any immunosuppressive treatment.
  • the used of mAbs may eventually lead to permanent
  • the myogenic and the non myogenic cells may be any type of myogenic and the non myogenic cells.
  • founders may also be facilitated by introducing in the founder
  • cloned cells may also prevent undesired
  • a mouse cell line MB3 has been produced which
  • transplanted cells by introducing a ⁇ -IFN inducible SV40 T antigen may be subject to variation, as will be
  • reaction may be effected on a biopsy.
  • cDNAs so amplified may have a differential restriction
  • transplanted myoblasts may be monitored by way of
  • the amount of cells to be injected may depend of
  • the muscle may be facilitated by developing a device
  • This robotic device may receive
  • the imaging system e.g. magnetic scanner
  • the cells required to treat the muscle may also be treated.
  • Some type of cells may be inserted by some other routes.
  • the solution to inject the cells may range from
  • the injection solution may also contains
  • invention is to enhance the early survival rate of
  • mice are an animal model of Duchenne
  • this animal model lacks dystrophin due to a
  • myoblasts may be grown from a muscle biopsy of an
  • the host may be im uno-
  • Myogenic cells have been shown to be able to form
  • the injected myoblasts can be
  • new muscle fibers can be formed in a primate.
  • retrovirus vector containing the ⁇ -galactosidase gene
  • Duchenne muscular dystrophy is due to the absence
  • the protein can be any of dystrophin in the muscle fibers.
  • the protein can be any of dystrophin in the muscle fibers.
  • the protein can be any of dystrophin in the muscle fibers.
  • the protein can be any of dystrophin in the muscle fibers.
  • the protein can be any of dystrophin in the muscle fibers.
  • the protein can be any of dystrophin in the muscle fibers.
  • the protein can be any of dystrophin in the muscle fibers.
  • the muscular dystrophy in dy/dy mice is due to the
  • Muscular Dystrophy (Arahata et al . 1993; Sunada et al .
  • merosin can be restored by the transplantation in the
  • extracellular matrix stabilizes the muscle fibers.
  • mice The C57BL/6J dy/dy mice (Jackson Lab.) were used as the mice.
  • the transgenic TnI-LacZV29 mice (Tn-LacZ, gift from
  • ⁇ -gal cytoplasmic ⁇ -galactosidase
  • ⁇ -gal expression is not restricted to the nucleus in
  • the H-2K b -tsA58 transgenic mice carry the
  • thermolabile tsA58 mutant of SV40 large T antigen under
  • Interferon Y (IFN- ⁇ ) increases the transcription of this
  • thermolabile protein is functionally
  • H-2K -tsA58 male mouse (Charles River Lab., Wilmington,
  • the cell suspension was cultured in 199 medium (Gibco, Grand Island, NY)
  • FCS concentration to 5% and growing the cells at 37°C in
  • Tibialis anterior (TA) muscles were exposed and injected
  • transplantation three days before transplantation, one
  • histochemistry was as sensitive as three-step
  • the second antibody was FITC-conjugated rabbit anti-mouse IgG (1/100 in PBS
  • hybrid muscle fibers expressing ⁇ -gal hybrid muscle fibers expressing ⁇ -gal. These ⁇ -gal
  • LAMA2-positive fibers was low (mean ⁇ SD, 6.4 ⁇ 4.4)
  • the Tn-LacZ primary muscle cultures originate from
  • mice with normal LAMA2 expression mice with normal LAMA2 expression.
  • LAMA2 and ⁇ -gal were present in the donor cells.
  • LAMA2 and ⁇ -gal were present in the donor cells.
  • LAMA2-positive fibers were
  • LAMA2 deposition also presented important
  • mice without inducing tumors.
  • the transgenic myoblasts are mice, without inducing tumors.
  • mice were able to grow and proliferate at 33°C in a 10% C0 2 atmosphere when stimulated by murine IFN- ⁇ .
  • filament desmin which is an early marker of myoblasts
  • myoblasts were thus able to fuse together or with host
  • LAMA2-surrounded fibers were obtained when young animals
  • mice mice were treated with mdx/mdx (Wakeford et al . , 1991) mice. This treatment
  • mRNA are detected in untreated dy/dy mice by RT-PCR
  • LAMA2 LAMA2
  • transplantation is less efficient in dy/dy mouse than in
  • the dy/dy muscle fibers are smaller than
  • the myoblast proliferation and/or migration could be any type of myoblast proliferation and/or migration.
  • LAMA2 was generally more
  • ⁇ -gal expression is restricted to skeletal muscle cells
  • myoblasts or fibroblast-like, or both cell types in the
  • ⁇ -gal positive or LAMA2-positive, or both ⁇ -gal and
  • LAMA2-positive fibers should be observed. LAMA2 expression pa t tern
  • LAMA2 may diffuse, thus producing a gradient of LAMA2
  • LAMA2 is also less in small-diameter than
  • LAMA2 may be secreted by
  • myogenic cells as are other muscle proteins and
  • muscle regeneration that is, myoblast proliferation, alignment or fusion, or the stability of nerve-muscle
  • LAMA2-secreting cell is a connective cell, with no
  • herpesviruses should indicate if it could constitute a
  • Myoblast transplantation may indeed be
  • transplantation may be used to treat Huntington disease
  • islet may be use for diabetic (Hering
  • myoblasts were transplanted in a host previously
  • mice ⁇ -Gal labelled myoblasts were injected in mice
  • cells/section i.e. macrophages and
  • neutrophils The presence of neutrophils was also
  • the death of the transplanted cell is due to an
  • transplanted cells was, however, significantly reduced to only 18.2 ⁇ 7.2% by injecting the host with a mAb

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne une méthode pour améliorer les chances de réussite d'une transplantation. Cette invention vise à résoudre, en particulier, un des problèmes les plus sérieux rencontrés lors de transplantations, qui est celui de la survie du transplant. La méthode consiste à transplanter les cellules du donneur sur un patient nécessitant une telle transplantation, la transplantation étant faite en présence d'un agent bloquant l'interaction entre une molécule ICAM-1, se trouvant sur la surface de la membrane des cellules du donneur et la molécule LFA-1, située sur la surface des membranes des leucocytes du patient, ce blocage améliorant la viabilité desdites cellules transplantées du donneur par un facteur d'au moins quatre. L'agent bloquant cette interaction est un anticorps anti-LFA-1 qui est injecté à l'hôte au moment de la transplantation ou un fragment d'anticorps anti-ICAM-1 qui n'est pas capable de fixer le complément, par exemple le fragment F(ab)2.
PCT/CA1996/000191 1996-03-29 1996-03-29 Procede pour reconstituer une proteine fonctionnelle dans un tissu par transplantation de cellules Ceased WO1997036602A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU51401/96A AU5140196A (en) 1996-03-29 1996-03-29 Method of restoring a functional protein in a tissue by cell transplantation
PCT/CA1996/000191 WO1997036602A1 (fr) 1996-03-29 1996-03-29 Procede pour reconstituer une proteine fonctionnelle dans un tissu par transplantation de cellules
EP96907971A EP0896542A1 (fr) 1996-03-29 1996-03-29 Procede pour reconstituer une proteine fonctionnelle dans un tissu par transplantation de cellules
CA002260808A CA2260808A1 (fr) 1996-03-29 1996-03-29 Procede pour reconstituer une proteine fonctionnelle dans un tissu par transplantation de cellules

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CA1996/000191 WO1997036602A1 (fr) 1996-03-29 1996-03-29 Procede pour reconstituer une proteine fonctionnelle dans un tissu par transplantation de cellules

Publications (1)

Publication Number Publication Date
WO1997036602A1 true WO1997036602A1 (fr) 1997-10-09

Family

ID=4173145

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1996/000191 Ceased WO1997036602A1 (fr) 1996-03-29 1996-03-29 Procede pour reconstituer une proteine fonctionnelle dans un tissu par transplantation de cellules

Country Status (3)

Country Link
EP (1) EP0896542A1 (fr)
AU (1) AU5140196A (fr)
WO (1) WO1997036602A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999030730A1 (fr) * 1997-12-15 1999-06-24 Universite Laval Procedes et compositions permettant d'ameliorer la reussite de la transplantation cellulaire chez un receveur

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993024151A1 (fr) * 1992-05-29 1993-12-09 The General Hospital Corporation Injection de myoblastes par voie arterielle
WO1994004188A1 (fr) * 1992-08-21 1994-03-03 Genentech, Inc. Procede pour traiter une affection ayant pour origine l'antigene 1 associe a la fonction lymphocytaire
WO1995014079A1 (fr) * 1993-11-16 1995-05-26 Indiana University Foundation Greffes myocardiques et compositions cellulaires utiles pour lesdites greffes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993024151A1 (fr) * 1992-05-29 1993-12-09 The General Hospital Corporation Injection de myoblastes par voie arterielle
WO1994004188A1 (fr) * 1992-08-21 1994-03-03 Genentech, Inc. Procede pour traiter une affection ayant pour origine l'antigene 1 associe a la fonction lymphocytaire
WO1995014079A1 (fr) * 1993-11-16 1995-05-26 Indiana University Foundation Greffes myocardiques et compositions cellulaires utiles pour lesdites greffes

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
A. CHAHINE ET AL.: "Immunomodulation of pancreatic islet allografts in mice with CTLA4Ig secreting muscle cells.", TRANSPLANTATION, vol. 59, no. 9, 1995, BALTIMORE, MD, USA, pages 1313 - 1318, XP000611823 *
A. TALENTO ET AL.: "A single administration of LFA-1 antibody confers prolonged allograft survival.", TRANSPLANTATION, vol. 55, no. 2, February 1993 (1993-02-01), BALTIMORE, MD, USA, pages 418 - 422, XP002019790 *
B. GUÉRETTE ET AL.: "Prevention of immune reactions triggered by first-generation adenoviral vectors by monoclonal antibodies and CTLA4Ig.", HUMAN GENE THERAPY, vol. 7, no. 12, 1 August 1996 (1996-08-01), NEW YORK, NY, USA, pages 1455 - 1463, XP000611510 *
H. YANG ET AL.: "Prolongation of rat islet allograft survival by treatment with monoclonal antibodies against VLA-4 and LFA-1.", TRANSPLANTATION, vol. 60, no. 1, 15 July 1995 (1995-07-15), BALTIMORE, MD, USA, pages 71 - 76, XP000611504 *
I. KINOSHITA ET AL.: "Myoblast allotransplantation in primates.", MUSCLE AND NERVE, vol. 18, no. 10, October 1995 (1995-10-01), BOSTON, MA, USA, pages 1217 - 1218, XP000611723 *
J-T. VILQUIN ET AL.: "FK506 immunosuppression to control the immune reactions triggered by first generation adenovirus-mediated gene transfer.", HUMAN GENE THERAPY, vol. 6, no. 11, November 1995 (1995-11-01), NEW YORK, NY, USA, pages 1391 - 1401, XP000611509 *
M. ISOBE ET AL.: "Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1.", SCIENCE, vol. 255, no. 5048, 28 February 1992 (1992-02-28), WASHINGTON, DC, USA, pages 1125 - 1127, XP002019791 *
Y. ZENG ET AL.: "Inhibition of transplant rejection by pretreatment of xenogeneic pancreatic islet cells with anti-ICAM-1 antibodies.", TRANSPLANTATION, vol. 58, no. 6, 27 September 1994 (1994-09-27), BALTIMORE, MD, USA, pages 681 - 689, XP000611506 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999030730A1 (fr) * 1997-12-15 1999-06-24 Universite Laval Procedes et compositions permettant d'ameliorer la reussite de la transplantation cellulaire chez un receveur

Also Published As

Publication number Publication date
AU5140196A (en) 1997-10-22
EP0896542A1 (fr) 1999-02-17

Similar Documents

Publication Publication Date Title
Torrente et al. Intraarterial injection of muscle-derived CD34+ Sca-1+ stem cells restores dystrophin in mdx mice
Alliot et al. Microglia derive from progenitors, originating from the yolk sac, and which proliferate in the brain
Jiang et al. Laminin-1 promotes differentiation of fetal mouse pancreatic beta-cells.
Vilquin et al. Successful histocompatible myoblast transplantation in dystrophin-deficient mdx mouse despite the production of antibodies against dystrophin.
AU688427B2 (en) Myocardial grafts and cellular compositions useful for same
Vilquin et al. Partial laminin alpha2 chain restoration in alpha2 chain-deficient dy/dy mouse by primary muscle cell culture transplantation.
Nakao et al. Tenascin-C promotes healing of Habu-snake venom-induced glomerulonephritis: studies in knockout congenic mice and in culture
Huard et al. Human myoblast transplantation in immunodeficient and immunosuppressed mice: evidence of rejection
JP2004511209A (ja) 細胞の脱分化及び組織の再生のための組成物及び方法
JP2011219494A (ja) 筋細胞、及び心臓修復におけるそれらの利用
IL293552A (en) Modulators of the immune escape mechanism for universal cell therapy
US20150139994A1 (en) Compositions and methods for preventing allogeneic immune rejection
Anandagoda et al. Dominant regulation of long-term allograft survival is mediated by microRNA-142
Vilquin et al. Myoblast transplantations lead to the expression of the laminin α2 chain in normal and dystrophic (dy/dy) mouse muscles
Geissler et al. Effective use of donor MHC class I gene therapy in organ transplantation: prevention of antibody-mediated hyperacute heart allograft rejection in highly sensitized rat recipients
US7022321B2 (en) Use of marrow-derived glial progenitor cells as gene delivery vehicles into the central nervous system
Qian et al. A promising technique for transplantation of bone marrow-derived endothelial progenitor cells into rat heart
WO1999030730A1 (fr) Procedes et compositions permettant d'ameliorer la reussite de la transplantation cellulaire chez un receveur
Smythe et al. Absence of MyoD increases donor myoblast migration into host muscle
WO1997036602A1 (fr) Procede pour reconstituer une proteine fonctionnelle dans un tissu par transplantation de cellules
Kinoshita et al. Mechanism of increasing dystrophin-positive myofibers by myoblast transplantation: study using mdx/β-galactosidase transgenic mice
CA2260808A1 (fr) Procede pour reconstituer une proteine fonctionnelle dans un tissu par transplantation de cellules
GB2293604A (en) Dermal fibroblast cells, convertable to myoblast cells, may comprise muscle-speicific DNA
Partridge Myoblast transplantation
Adigbli et al. Transplantation Publish Ahead of Print

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1996907971

Country of ref document: EP

NENP Non-entry into the national phase

Ref document number: 97534756

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2260808

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2260808

Country of ref document: CA

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1996907971

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996907971

Country of ref document: EP